Latest News and Press Releases

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg...

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show...

·L’Agence canadienne des médicaments et des technologies de la santé (ACMTS) a élargi ses recommandations concernant le financement par les fonds publics du traitement des patients atteints...

·Canadian Association of Drugs and Technologies in Health (CADTH) has expanded their recommendations for public reimbursement for SMA patients ·The recommendation, however, continues to limit access...

MISSISSAUGA, Ontario, 20 déc. 2018 (GLOBE NEWSWIRE) -- Cette décision découle de la recommandation positive de l’Institut national d’excellence en santé et services sociaux (INESSS) qui...

The decision follows positive recommendation from the Institut national d'excellence en santé et services sociaux (INESSS) recognising the urgency and need for a treatment for patients with SMA and...